论文部分内容阅读
分析近几年关于氟尿嘧啶大分子前体药物肿瘤靶向的研究进展,并以载体为分类展开讨论。提出大分子前体药物研究进一步发展面临的问题和挑战。目前已有多种大分子载体可应用于氟尿嘧啶大分子前体药物,且具有良好的性质,但为了能在临床上得到更广泛的应用,还需要近一步的药代研究。
In recent years, the research progress on the tumor targeting of fluorouracil prodrugs has been analyzed and the classification of carriers has been discussed. The problems and challenges in the further development of research on macromolecular prodrugs are proposed. At present, a variety of macromolecular carriers have been applied to fluorouracil macromolecular prodrugs and have good properties. However, in order to be more widely used clinically, further pharmacokinetic studies are needed.